Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems
File version
Author(s)
Khatri, Januka
Shakya, Sujyoti
Danekhu, Krisha
Khatiwada, Asmita Priyadarshini
Sah, Ranjit
Bhuvan, KC
Paudyal, Vibhu
Khanal, Saval
Rodriguez-Morales, Alfonso J
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new species of β-coronavirus genus named severe acute respiratory syndrome coronavirus 2. The COVID-19 pandemic, which started in late 2019 and continues as at mid-2021, has caused enormous damage to health and lives globally. The urgent public health need has led to the development of vaccines against COVID-19 in record-breaking time. The COVID-19 vaccines have been widely rolled out for the masses by many countries following approval for emergency use by the World Health Organization and regulatory agencies in many countries. In addition, several COVID-19 vaccine candidates are undergoing clinical trials. However, myths, fears, rumors, and misconceptions persist, particularly in regard to adverse events. In this commentary, we describe the adverse events associated with COVID-19 vaccines and discuss why it is essential to have a functional adverse event monitoring system in this context.
Journal Title
Drugs & Therapy Perspectives
Conference Title
Book Title
Edition
Volume
37
Issue
8
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Pharmacology and pharmaceutical sciences
Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
SAFETY
Persistent link to this record
Citation
Shrestha, S; Khatri, J; Shakya, S; Danekhu, K; Khatiwada, AP; Sah, R; Bhuvan, KC; Paudyal, V; Khanal, S; Rodriguez-Morales, AJ, Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems, Drugs & Therapy Perspectives, 2021, 37 (8), pp. 376-382